Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study

OBJECTIVES: One of the most significant features of poor prognosis in COVID-19 is pulmonary fibrosis. Nintedanib is a new antifibrotic agent that interferes with processes of pulmonary fibrosis. This study aimed to investigate the efficacy and safety of nintedanib in COVID-19. METHODS: This was an i...

Descripción completa

Detalles Bibliográficos
Autores principales: Umemura, Yutaka, Mitsuyama, Yumi, Minami, Kensuke, Nishida, Takeshi, Watanabe, Atsushi, Okada, Naoki, Yamakawa, Kazuma, Nochioka, Kotaro, Fujimi, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146615/
https://www.ncbi.nlm.nih.gov/pubmed/34048887
http://dx.doi.org/10.1016/j.ijid.2021.05.055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146615/
https://www.ncbi.nlm.nih.gov/pubmed/34048887
http://dx.doi.org/10.1016/j.ijid.2021.05.055

Ejemplares similares